References in periodicals archive ?
Green Cross filed for regulatory approval with the KFDA for recombinant Factor VIII in the second quarter of 2008 and Green Cross has completed Phase III studies for erythropoetin.
Some of Locus Discovery's drug design programs include small molecule mimetics of erythropoetin, anti-viral compounds based on a novel target called GP41, and other programs in cancer, infectious diseases, asthma, and neurological and other disorders.
and Canada: erythropoetin, pegylated G-CSF (granulocyte-colony stimulating factor), Interferon-Alpha, recombinant Factor VIII, and Enbrel([R]) (etanercept).
Some of Locus Discovery's drug discovery programs include small molecule mimetics of erythropoetin, anti-viral compounds based on a novel target called GP41, and other programs in cancer, infectious diseases, and neurological and other disorders.
Green Cross plans to file for regulatory approval with the Korean FDA for recombinant Factor VIII in the first quarter of 2008, and Green Cross has completed Phase III studies for erythropoetin.
The authors found that treatment of these patients with Erythropoetin significantly improved the symptoms of these patients.
Some of the more advanced drug discovery programs include small molecule mimetics of erythropoetin, and broad-spectrum anti-viral compounds based on a novel anti-viral target called GP41.
Roche is offering free antibody testing to physicians for those patients in whom there are concerns that anti-erythropoetin antibodies may have already developed with other erythropoetin therapy.
Some of the more advanced drug discovery programs include a small molecule mimetic of erythropoetin, and a broad spectrum anti-viral compound based on a novel anti-viral target called GP41.
Dragon Pharmaceuticals (the "Company) is pleased to announce a number of significant developments in its international marketing of Erythropoetin ("EPO") since its last international marketing update on October 6, 2000.
Small molecule erythropoetin mimetic -- One of the most successful and largest selling biotechnology products in the world is erythropoetin, sold by Amgen as Epogen(R) and Johnson & Johnson as Procrit(R).